The NCMAG Council makes decisions on the proposed use of cancer medicines.
These medicines uses are planned for review by NCMAG:
NCMAG121 – Nivolumab in combination with Ipilimumab
For neoadjuvant treatment of resectable stage 3 melanoma (off-label use)
- Council meeting date: 20 March 2025
- Planned publication date: 24 April 2025
NCMAG122 – Pembrolizumab
For neoadjuvant treatment of stage 3B to 3D or oligometastatic resectable stage 4 melanoma (off-label use)
- Council meeting date: 20 March 2025
- Planned publication date: 24 April 2025
NCMAG123 – Bevacizumab
In combination with fluoropyrimidine-based chemotherapy for the first line treatment of adult patients with metastatic carcinoma of the colon or rectum. (on-label use and off-patent medicine)
- Council meeting date: 19 June 2025
- Planned publication date: 24 July 2025
NCMAG124 – Bevacizumab
In combination with fluoropyrimidine-based chemotherapy for the second line treatment of adult patients with metastatic carcinoma of the colon or rectum. (on-label use and off-patent medicine)
- Council meeting date: 19 June 2025
- Planned publication date: 24 July 2025
NCMAG125 – Paclitaxel
For use in combination with pertuzumab plus trastuzumab in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease, and who are considered not fit enough for, or cannot tolerate docetaxel in this combination. (off-label use and off-patent medicine)
- Council meeting date: 18 September 2025
- Planned publication date: 23 October 2025